title: Reduced parathyroid functional mass after successful kidney transplantation.
abstract: BACKGROUND
  Chronic uremia is responsible for secondary hyperparathyroidism (HPT II). Parathyroid secretion usually tends to normalize after kidney transplantation (KT), but the parameters of the reversibility of HPT II remain poorly defined, particularly the intrinsic mechanisms underlying the improvement of parathyroid function.
  
  
  METHODS
  The kinetic functional parameters of the ionized calcium (iCa)/parathormone (PTH) relationship curve were studied in 11 patients with mild to moderate HPT II one and six months after successful KT. Hypercalcemia and hypocalcemia were induced, respectively, by CaCl2 and Na2-ethylenediaminetetraacetic acid (Na2-EDTA) infusions.
  
  
  RESULTS
  The mean glomerular filtration rate remained stable during follow-up. Basal PTH decreased from 195 +/- 54 pg/ml before KT to 70 +/- 12 pg/ml six months later (P < 0. 005). During the tests, mean PTH levels decreased significantly between the two measured times for all iCa levels, indicating an improved parathyroid function. An analysis of the kinetic parameters of the curves showed significant decreases of the mean maximal and minimal PTH levels, respectively, from 340 +/- 91 to 220 +/- 30 pg/ml (P = 0.03) and from 25 +/- 6 to 15 +/- 5 pg/ml (P = 0.005). On the other hand, no change was noted in the parathyroid-cell calcium-sensitivity parameters (slope, set point) assessed using two different approaches, either the entire curve or the limited calcium-mediated suppression curve.
  
  
  CONCLUSIONS
  Improvement of the parathyroid function between the first and sixth months post-KT seems mainly attributable to a reduction of the parathyroid functional mass.
authors.affiliation: Service de Néphrologie et Transplantation Rénale, Hôpital Pelligrin, Centre Hospitalier Universitaire, Bordeaux, France.
authors.forename: H
authors.initials: H
authors.lastname: Bonarek
authors.forename: P
authors.initials: P
authors.lastname: Merville
authors.forename: M
authors.initials: M
authors.lastname: Bonarek
authors.forename: K
authors.initials: K
authors.lastname: Moreau
authors.forename: D
authors.initials: D
authors.lastname: Morel
authors.forename: M
authors.initials: M
authors.lastname: Aparicio
authors.forename: L
authors.initials: L
authors.lastname: Potaux
mesh_terms: D000328:Adult; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000097:blood; D002122:Calcium Chloride / Q000008:administration & dosage; D004492:Edetic Acid / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000473:pathology / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010280:Parathyroid Glands / Q000378:metabolism / Q000473:pathology*; D010281:Parathyroid Hormone / Q000097:blood / Q000378:metabolism; D011183:Postoperative Complications / Q000473:pathology*
chemical_list: D010281:Parathyroid Hormone; D004492:Edetic Acid; D002122:Calcium Chloride; D002118:Calcium